Obesity and Medical Marijuana: What Research Shows
Obesity is a chronic disease, and medical cannabis is not a treatment for it. THC, the main active compound in cannabis, raises appetite through the CB1 receptor in every form it comes in, smoked, vaped, eaten or held under the tongue. None of the human studies behind this page tested cannabis as a way to lose weight. The cannabinoid drug that was studied most for obesity, rimonabant, did the opposite of THC: it blocked CB1, and it was taken off the market because of psychiatric side effects [1][2].
Built on peer-reviewed research published between 1978 and 2026, from laboratory work to trials in people.
If you are here, your weight is probably already doing more than changing a number on the scale. Knees that ache on the stairs, nights that end tired, getting out of breath on a short walk, a blood pressure reading that keeps creeping up. You have likely seen the online promises too, “cannabis for weight loss” among them, and the diets that worked for a month. And you may have sat in an exam room bracing for a lecture rather than help.
This page does not promise a shortcut. It lays out what obesity is, what it does to the body, and what the research on cannabinoids and weight really found, strongest evidence first. Then it shows where a conversation with a licensed physician fits, and where it does not.
Start from your situation
What is obesity? Definition, classes and BMI chart
Obesity is a chronic disease in which body fat has built up to a level that harms health [3]. “Chronic” is the important word: it is not a phase or a failure of willpower, and it is managed over years, the way blood pressure or diabetes is.
In adults, obesity is screened for with the body mass index, or BMI. It is your weight divided by the square of your height; in US units, weight in pounds times 703, divided by height in inches squared. A BMI of 30 or higher is in the obesity range, and 25 to under 30 is overweight [4]. By that measure, 40.3% of adults in the United States had obesity between August 2021 and August 2023, and 9.4% had severe obesity [5].
Obesity class 1, 2 and 3
Above a BMI of 30, clinicians split obesity into three classes. Class 1 runs from 30 to under 35, class 2 from 35 to under 40, and class 3 is 40 or higher [4]. Class 3 is what older charts called “severe” or “morbid” obesity; since October 2024 each class has its own diagnosis code, so the record can say the class instead [6]. The class describes a range of health risk, which rises from one class to the next. It does not describe a person.
What weight range is each class at your height?
How to read it: set your height, and the right-hand column shows the weight range in pounds that falls into each BMI category at that height. Nothing is stored, and the chart does not place you in a class; that takes a measured weight and a clinician who sees the whole picture.
Measured without shoes; the height on your driver’s license works.
| Category | BMI | Set your height |
|---|---|---|
| Underweight | Under 18.5 | — |
| Healthy weight | 18.5 to 24.9 | — |
| Overweight | 25 to 29.9 | — |
| Obesity, class 1 | 30 to 34.9 | — |
| Obesity, class 2 | 35 to 39.9 | — |
| Obesity, class 3 | 40 or higher | — |
To find the weight range for your height without the slider: multiply your height in inches by itself, multiply that by the BMI at each edge of the row, and divide by 703. At 5 ft 7 in (67 inches), for example, class 1 obesity starts at 30 × 67 × 67 ÷ 703, which is about 192 lb.
| Women | Men |
|---|---|
| More than 35 inches | More than 40 inches |
Is the obesity chart different for women?
For adults, no. The BMI cutoffs for overweight and for each obesity class are the same for women and men, and the chart above applies to both [4]. What differs is the waist. Fat stored around the middle carries more risk of type 2 diabetes and heart disease than fat stored elsewhere, and the waist size where that risk rises is lower for women, above 35 inches, than for men, above 40 inches [7]. Measure just above the hip bones, after breathing out.
Children and teenagers are different again. Their BMI is read against growth charts for their age and sex, as a percentile, because a child’s body composition changes as they grow [8].
What BMI cannot tell you
BMI counts weight, not fat. A muscular athlete can land in the overweight range with little body fat, while an older adult who has lost muscle can sit in the “healthy” range and still carry too much fat around the organs. It also says nothing about where fat sits, and it does not show blood pressure, blood sugar or cholesterol. That is why a physician pairs it with a waist measurement, blood tests and your history before calling it a diagnosis [4].
Obesity ICD-10 codes
Every diagnosis in a US medical record carries a code from ICD-10-CM, the classification that clinicians and insurers use. For obesity there are two families. Codes beginning with E66 name the diagnosis itself; codes beginning with Z68 record the adult BMI at the visit. Since October 1, 2024, the three obesity classes have their own E66 codes, and CDC asks clinicians to use them together with a Z68 code [6]. The table below follows the current code set published by CMS [10].
| Code | What it means | When it is used |
|---|---|---|
E66.811 | Obesity, class 1 | Adult BMI 30 to under 35 |
E66.812 | Obesity, class 2 | Adult BMI 35 to under 40 |
E66.813 | Obesity, class 3 | Adult BMI 40 or higher |
E66.01 | Morbid (severe) obesity due to excess calories | Older wording for severe obesity; still in the code set |
E66.2 | Morbid (severe) obesity with alveolar hypoventilation | Obesity with shallow breathing that raises carbon dioxide; see obesity hypoventilation syndrome |
E66.3 | Overweight | Adult BMI 25 to under 30 |
E66.9 | Obesity, unspecified | Obesity recorded without a class or cause |
Z68.25–Z68.29 | Adult BMI 25.0 to 29.9 | One code per whole BMI point |
Z68.30–Z68.39 | Adult BMI 30.0 to 39.9 | One code per whole BMI point |
Z68.41 | Adult BMI 40.0 to 44.9 | The usual pair for class 3 at BMI 40 |
Z68.42 | Adult BMI 45.0 to 49.9 | With a class 3 code |
Z68.43 | Adult BMI 50.0 to 59.9 | With a class 3 code |
Z68.44 | Adult BMI 60.0 to 69.9 | With a class 3 code |
Z68.45 | Adult BMI 70 or greater | With a class 3 code |
No codes in that group.
Why this matters for you: when a physician evaluates you for a medical marijuana card, what they match against your state’s list is a diagnosis, not a number on a scale. If your records already carry an obesity code, and especially codes for conditions that travel with it, such as osteoarthritis, sleep apnea or chronic pain, bring them. A visit summary or a problem list from your regular doctor is usually enough, and it saves the appointment from guessing.
What causes obesity? Is obesity genetic?
At its simplest, weight rises when the body takes in more energy than it uses, over months and years. But “eat less, move more” explains very little about why that happens to one person and not another. NIDDK, the federal institute that studies the disease, lists a much longer chain of causes [11].
- Food and daily routine. Calorie-dense food and drink that is cheap and everywhere, and work and commutes that keep people sitting most of the day [11].
- Sleep. Adults need 7 to 9 hours. Short sleep raises hunger and the calories eaten the next day [11].
- Stress and mood. Long-term stress and depression change eating and activity, and binge-eating disorder is a cause in its own right [11].
- Medicines. Some drugs for epilepsy, depression and psychotic disorders, corticosteroids, insulin and sulfonylureas for diabetes, several blood pressure drugs and some antihistamines can all add weight [11]. Do not stop any of them on your own; ask whether an alternative exists.
- Hormones and other conditions. An underactive thyroid (hypothyroidism), polycystic ovary syndrome (PCOS) and Cushing’s syndrome are among the medical conditions that raise weight [11].
Is obesity genetic?
Partly, and in a small group of people almost entirely. Family history raises the odds, and many genes each nudge appetite and fat storage a little [11]. A few single genes do much more. The best known is MC4R, the gene for a brain receptor that tells you that you have eaten enough. When it does not work, hunger stays switched on from early childhood.
How the MC4R study was done
Researchers sequenced the MC4R gene in 7,719 children from the Genetics of Obesity Study, found 316 with a loss-of-function variant, and added 144 adult family members who carried one too. They compared them with 336,728 people from the UK Biobank. The surprise was that obesity caused by MC4R deficiency came with lower cholesterol, lower triglycerides and a lower risk of cardiovascular disease than the same weight usually brings [12].
The part that ties back to this page: MC4R sits on the same hunger circuits as the CB1 receptor that THC acts on. Both are switches in one system, and the research on them is mostly about how appetite is wired, not about treatment.
Genes in the cannabinoid system itself have been studied as well, with mixed results. In 2,415 adults from the Framingham Offspring Study, common variants in CNR1, the gene for the CB1 receptor, and FAAH, the gene for an enzyme that clears the body’s own cannabinoids, showed no clear link with body fat measures [13]. A smaller cross-sectional study found one FAAH variant somewhat more often in people with obesity (odds ratio 1.40, 95% CI 1.01–1.96) [14]. Signals like these describe populations, not an individual’s fate.
Food insecurity and homelessness
Where you live and what you can afford shape weight as much as any gene. When money is short, the cheapest calories are the most processed ones; a neighborhood without a full grocery store, safe sidewalks or a park leaves fewer choices still [11]. People without stable housing face all of this at once, often with no way to store or cook fresh food and little control over when they eat or sleep. None of it is a personal failing, and a good clinician asks about it before giving advice that assumes a kitchen and a quiet night.
Check how your situation fits with a few questions below.
Is my situation one where a medical card could fit, and what should I raise first?
Twelve questions about your weight, your health and your medicines. At the end you get a plain reading of what your answers point to, what the research says about that situation, and what to raise with a physician. Nothing is stored against your name, and this is not a diagnosis.
12 questions · about a minute · your answers stay in this browser
Obesity effects on health: does obesity cause…?
Is obesity dangerous? Over time, it raises the risk of a long list of conditions: type 2 diabetes, high blood pressure, heart disease and stroke, fatty liver, kidney disease, osteoarthritis, gout, sleep apnea and several cancers, as well as depression and low self-esteem [9]. Some people with obesity have normal blood pressure, blood sugar and cholesterol for years, which is why risk is judged person by person rather than from weight alone. Below are the questions people search for most, each answered in a few sentences. Pick a body system to narrow the list.
Does obesity cause high blood pressure?
Often, yes. Extra weight makes the heart pump harder to move blood through a larger body, and over time it can damage the kidneys, which help keep blood pressure in range [9]. The good news runs the other way too: blood pressure usually falls as weight comes down, sometimes enough to reduce medication, but only your prescriber should change a dose.
What does obesity do to BNP?
BNP and NT-proBNP are blood tests used to look for heart failure. People with obesity tend to have lower levels of both, even when the heart is struggling, so a “normal” result can be falsely reassuring [15]. If you have swelling in the legs or get breathless lying flat, say so, and ask how your result was read in light of your weight.
Does obesity cause diabetes?
It is the strongest single risk factor for type 2 diabetes: nearly 9 in 10 people with type 2 diabetes have overweight or obesity [9]. In people at risk, losing 5% to 7% of body weight with more activity can prevent or delay it [9]. Type 1 diabetes is a different, autoimmune disease and is not caused by weight.
How does obesity cause insulin resistance?
Insulin resistance means muscle, fat and liver cells respond less to insulin, so the pancreas has to make more to keep blood sugar normal. Overweight, obesity and a large waist are among its main risk factors [16]. For years blood sugar can stay normal while the pancreas works harder; over time it may not make enough insulin to keep up, and prediabetes and then type 2 diabetes follow [16].
Does obesity cause PCOS?
Not on its own; polycystic ovary syndrome is a hormonal condition with a strong family pattern. But the two feed each other. Insulin resistance is common in PCOS, PCOS makes weight easier to gain and harder to lose, and extra weight makes symptoms such as irregular periods worse [17]. Losing some weight can make cycles more regular [17].
Does obesity affect fertility?
In women, obesity is linked to problems with the menstrual cycle and ovulation; in men, to lower sperm count and quality [9]. In women whose periods have stopped or become irregular, losing about 5% of body weight may bring ovulation back [9]. Obesity also raises the risk of gestational diabetes and preeclampsia during pregnancy [9].
Does obesity cause erectile dysfunction?
It raises the risk [9]. An erection depends on healthy blood vessels and normal hormone levels, and obesity strains both, directly and through the diabetes, high blood pressure and lower testosterone that often come with it [18]. Erectile problems can be an early sign of vascular disease, so they are worth raising even if they feel awkward to mention.
Does obesity increase estrogen in males?
Yes. Fat tissue contains aromatase, an enzyme that turns testosterone into estradiol, a form of estrogen, and men with obesity have more of it [18]. The extra estradiol signals the brain to slow the body’s own testosterone production, which can lower libido and energy and make fat easier to store [18].
Does obesity cause shortness of breath?
It can. Weight on the chest and abdomen limits how far the lungs expand, so breathing takes more effort, and obesity raises the risk of asthma and makes its symptoms worse [9]. Breathlessness with daytime sleepiness and morning headaches can point to obesity hypoventilation syndrome [19]. New breathlessness at rest, or chest pain, needs medical care the same day.
Does obesity cause sleep apnea?
Obesity is a common cause of sleep apnea in adults [9]. Fat around the neck and upper airway narrows it, and the airway collapses again and again during sleep. The two conditions, and how they differ, are laid out side by side in the next section.
Does obesity cause cancer?
It raises the risk of at least 13 types of cancer, according to the National Cancer Institute: endometrial, esophageal, upper stomach, liver, kidney, pancreatic, colorectal, gallbladder, postmenopausal breast, ovarian and thyroid cancer, multiple myeloma and meningioma [20]. The link is strongest for endometrial and esophageal cancer [20]. Higher risk is not a certainty; screening on schedule matters more than worry.
Does obesity cause hair loss?
How does obesity cause GERD?
Extra weight around the abdomen presses on the stomach and pushes acid up into the esophagus, the cause of heartburn. Overweight and obesity are a recognized risk factor for gastroesophageal reflux disease, and losing weight is one of the first things clinicians suggest [22].
Does obesity compromise your immune system?
Excess fat keeps the body in a state of low-grade inflammation that dulls some immune responses. The clearest real-world signal came from COVID-19: in a CDC analysis, the risk of hospitalization and death rose step by step with BMI [23]. Staying current on vaccines matters more, not less, at a higher weight.
No questions in that group.
Living with joint pain or low mood as well? Cannabis and chronic pain · Cannabis and depression
Obesity hypoventilation syndrome and sleep apnea
Both of these are breathing disorders tied to obesity, both show up as snoring and daytime sleepiness, and most people with the second also have the first [19]. They are not the same thing, and the difference matters: one is about the airway closing at night, the other about the blood carrying too much carbon dioxide all day.
Obstructive sleep apnea
What happens: during sleep the soft tissue of the throat collapses and blocks the airway, breathing stops for seconds at a time, and the brain wakes you briefly to restart it, many times an hour [24].
Signs: loud snoring, gasping or choking at night, a partner noticing pauses, morning headaches and sleepiness during the day [24].
How it is diagnosed: a sleep study, either overnight in a lab or with a simple kit at home [24]. Treatment is usually a CPAP machine or an oral device, plus weight loss where possible.
Obesity hypoventilation syndrome
What happens: breathing is too shallow, even while awake, so carbon dioxide builds up in the blood and oxygen runs low. It was once called Pickwickian syndrome [19].
Signs: breathlessness, daytime drowsiness, fatigue, dizziness and headaches, with nighttime snoring and choking that get worse over time [19].
How it is diagnosed: a physical exam with BMI, waist and neck measures, lung function and blood gas tests, and a sleep study to look for apnea alongside it [19]. It is coded E66.2 and often treated with a breathing device every night [19].
Untreated, both disorders strain the heart and raise blood pressure, and both wreck sleep quality, so they often get mistaken for plain insomnia or depression. If you snore loudly and wake up unrefreshed, a sleep study is a better first step than any sleep aid.
How long has obesity been a problem in the US?
For about six decades of measurement, and it has grown the whole way. In the early 1960s, 13.4% of American adults aged 20 to 74 had obesity and 0.9% had severe obesity. By 2017–2018 those figures were 42.8% and 9.6% [25]. The most recent national survey shows the overall adult rate holding roughly flat over the last decade, at 40.3% in 2021–2023, while severe obesity kept climbing, from 7.7% to 9.7% after adjusting for age [5].
Childhood obesity
Between 2017 and March 2020, 19.7% of US children and teenagers aged 2 to 19 had obesity, about 14.7 million young people [8]. The share rises with age, from 12.7% of children aged 2 to 5 to 22.2% of those aged 12 to 19 [8]. Children are measured differently from adults, against growth charts for their age and sex [8], and they are never candidates for a medical marijuana card on this basis; cannabis use before adulthood is a risk in its own right.
Weight stigma and bullying
Being judged for your weight is not a side issue. People with obesity are teased at school, passed over at work and lectured in clinics, and that experience is linked to stress, low self-esteem and depression [9]. It also keeps people away from care: if every appointment turns into a talk about the scale, it is easy to stop going. For children and teenagers, teasing about weight at school lands at an age when self-image is still forming.
How long does obesity last?
For most adults, obesity is a long-term condition rather than an episode with an end date [3]. After weight loss, the body pushes back: hunger rises and energy use falls, which is why weight so often returns after a diet ends. That is not a lack of discipline; it is biology, and it is why obesity is managed over years, with nutrition, activity, sleep, medicines and sometimes surgery, the way blood pressure is.
When weight comes with worry or low mood: Cannabis and anxiety · Cannabis and depression
How cannabis affects appetite and weight
Your body makes its own cannabis-like molecules, called endocannabinoids. Together with the receptors they act on, CB1 and CB2, and the enzymes that clear them, they form the endocannabinoid system, which helps regulate food intake and energy balance [26]. Most of its effect on hunger runs through CB1 receptors in the brain.
THC switches CB1 on, and that is why it raises appetite [27]. This happens with any form of THC: a joint, a vape, a gummy or a tincture all deliver the same molecule to the same receptor. The timing and strength differ by form; the direction does not. So the first honest answer for anyone hoping to lose weight is that the main active compound in most medical cannabis pushes appetite up, not down.
CBD is a separate question. It does not switch CB1 on the way THC does, and what is known about THC and appetite does not carry over to a product that contains only CBD, or the other way around. CBD and other cannabinoids have been tested for weight-related effects, but only in animals and cells so far: CBD with swimming exercise in obese rats [28], hemp seed oil in human stem cells in a dish [29], and a lab-made relative of THCV, a minor cannabinoid, in zebrafish [30]. None of that tells us what CBD does to weight in people. It is being studied.
Two more names you may see are dronabinol (sold as Marinol and Syndros) and nabilone (Cesamet). They are prescription drugs approved by the FDA, made from or modeled on THC, and used to restore appetite in people with AIDS who are losing weight and to control nausea from chemotherapy [31]. They are prescribed by a doctor and filled at a pharmacy; they are not products sold under a medical marijuana card, and they are not weight-loss drugs.
For readers who want the biology: CB1, MC4R, ABHD6 and 2-AG
2-AG and ABHD6. 2-AG is the most plentiful endocannabinoid in the brain; ABHD6 is one of the enzymes that breaks it down. In animal studies, switching ABHD6 off in neurons of the nucleus accumbens, a reward center, prevented diet-induced obesity in male mice and reduced food seeking [32].
CB1 outside the brain. CB1 receptors also sit in fat tissue and the liver, where they favor fat storage. Blocking only these peripheral receptors, without entering the brain, reduced fat production and improved insulin sensitivity in the work summarized by a 2026 review [2]. In mice, heavy activation of the endocannabinoid system during adolescence disrupted how fat tissue worked in adulthood [33], and a protein called p62 was studied as one of the ways cells recycle CB1 [34].
The CB1 gene itself. A laboratory study found that a stretch of DNA controlling the CB1 gene behaves differently depending on which version a person carries, which may help explain why people respond to cannabinoid drugs differently [35]. In animal studies, even the amino acid taurine reduced fat buildup through the same CB1 pathway [36].
MC4R. The satiety receptor described in the genetics section sits downstream on the same hunger circuits. It is a different target from CB1, and drugs aimed at it are a separate line of research [2].
All of this is mechanism, much of it in animals or cells. It explains how appetite is wired; it does not show that any cannabis product helps a person lose weight.
The opposite problem, appetite that has disappeared: Cannabis and anorexia
What the research actually found
Studies are not equal. A randomized trial can show whether a drug caused a change; a survey can only show that two things went together; a study in mice shows how biology works in mice. What follows runs from the strongest evidence down, and it says plainly which studies were about cannabis and which were not.
Most of it is about blocking CB1, not about cannabis
When researchers studied cannabinoids for weight loss, they almost never studied cannabis. They studied rimonabant, a drug built to do the reverse of THC: instead of switching the CB1 receptor on, it blocks it. In the published work on cannabinoids and obesity, rimonabant comes up far more often than THC, CBD or cannabis itself. The two sides of that receptor look like this.
THC: switches CB1 on
Appetite: goes up, in every form of use [27].
What happened in people: no trial in people with obesity tested THC for weight loss. After bariatric surgery, people who used cannabis reported more anxiety and more binge eating than those who did not [27].
Status: available through state medical marijuana programs; prescription THC (dronabinol) is used to raise appetite, not to lower it [31].
Rimonabant: blocks CB1
Appetite: goes down; that was the point of the drug.
What happened in people: it was tested in trials as a weight-loss drug, and depressed mood and anxiety rose enough that people stopped taking it [2].
Status: withdrawn from the market because of psychiatric adverse events [1].
The dose there is what trial participants were given, not a guide to anything. The lesson is the mechanism: CB1 sits on circuits for mood as well as hunger, so a drug strong enough to shut down appetite from inside the brain also shut down something people needed. A 2026 laboratory study suggests one route: rimonabant at levels seen in treatment changed how genes are packed and read in neuronal cells and in rat brain tissue, raising one marker of that, histone H3 acetylation, 2.7-fold in cells [1]. Taranabant, a second brain-penetrant CB1 blocker of the same generation, now appears mostly as a reference molecule in laboratory structure studies (laboratory study) [37].
What studies of people who use cannabis show
The human evidence on cannabis itself and weight is thin, and none of it is a treatment trial. Three studies come closest.
A survey of people up to four years after bariatric surgery found that those who used cannabis reported anxiety more often (odds ratio 1.88) and binge eating more often (odds ratio 2.16) than those who did not [27]. A survey cannot say which came first.
A cohort study that followed mothers and their children, the Healthy Start study, found that children exposed to cannabis in the womb had somewhat more fat mass in early childhood (mean difference 1.0, 95% CI 0.3–1.7) [38]. That is about pregnancy, not about adults using cannabis, and it is one of the reasons pregnancy is on the list of who should not use it.
A cross-sectional study of US adolescents found that teens who used only marijuana were less likely to meet the guideline of no sugary drinks (odds ratio 0.81, 95% CI 0.65–0.99) [39]. Again, a snapshot of habits, not a measure of what cannabis does to weight.
Browse the studies yourself
Every study named on this page is below, with its design, who was in it, and what came out, including the neutral results and the ones that have nothing to do with cannabis. Filter by the kind of evidence you want to see.
New obesity drugs, including CB1 blockers that stay out of the brain
Surveys drugs beyond today’s injectables. Reports early human results for CRB-913 and nimacimab and the psychiatric side effects that ended rimonabant. Relies partly on conference posters and company releases, which the authors acknowledge [2].
Adolescent THC exposure and adult fat tissue
Pulls together mouse work showing that heavy activation of the endocannabinoid system in adolescence disrupted how fat tissue worked in adulthood. Animal evidence, not a finding in teenagers [33].
What role the endocannabinoid system plays in obesity
Explains how CB1 receptors and the FAAH enzyme help regulate food intake and energy balance, and why modulating the system has been tried as a treatment. Mixed conclusions [26].
Obesity from a broken satiety gene, MC4R
316 children carried a variant that switches MC4R off. Their obesity came with lower cholesterol, lower triglycerides and lower cardiovascular risk than usual. A genetics study, not a cannabis study [12].
A positive drug screen before bariatric surgery
Patients who screened positive needed more anesthetic and had more complications and readmissions within 30 days. Details in the safety section below [40].
Heart events in metabolically healthy obesity
In hospitalized Asian-American adults aged 18 to 44, obesity with normal metabolic markers did not raise major heart or brain events overall (odds ratio 0.98, 95% CI 0.70–1.37), but drug use within that group did [41].
Cannabis in pregnancy and the child’s body fat
Children exposed in the womb had somewhat more fat mass (mean difference 1.0, 95% CI 0.3–1.7). One more reason cannabis is avoided in pregnancy [38].
Risk-taking genes and BMI over adolescence
Followed teenagers’ BMI over time against variants in dopamine, serotonin and cannabinoid pathway genes; one variant, rs9567733, carried a higher obesity risk (hazard ratio 3.81, 95% CI 1.78–8.18) [42].
CB1 and FAAH gene variants and body fat
In the Framingham Offspring Study, common variants in the two genes showed no clear association with adiposity. A neutral result [13].
Racial and sex differences in cannabinoid receptor genes
One FAAH variant was somewhat more common with obesity (odds ratio 1.40, 95% CI 1.01–1.96), and several variants differed in frequency between African American and white participants [14].
Vaping, marijuana and obesity prevention guidelines
Teens who used only marijuana were less likely to meet the no-sugary-drinks guideline (odds ratio 0.81, 95% CI 0.65–0.99); mixed results on other habits [39].
A brain profile of BMI
Brain scans predicted a modest share of differences in BMI and lined up with impulsive decision-making. Not about cannabis; background on why appetite is not only willpower [43].
Cannabis use after bariatric surgery
People who used cannabis reported more anxiety (odds ratio 1.88) and more binge eating (odds ratio 2.16) than those who did not. A negative finding, and an association only [27].
Substance use in people with obesity during the pandemic
Substance use of any kind went together with stress eating, missed weight-loss goals, poor sleep, anxiety and depression. The full set of numbers is in the next section [44].
Weight and medical care during COVID-19
Adults with overweight and obesity reported weight gain and disrupted care during the pandemic. Background, not a cannabis study [45].
Tobacco 21 laws and young adults’ weight
About raising the tobacco purchase age, not about cannabis. Listed because it is part of the obesity literature; its figures are left off this page on purpose [46].
Exercise after bariatric surgery
Compared two training programs in patients with low muscle mass after surgery. No cannabinoid was involved; its numbers are not used on this page [47].
How peripheral CB1 blockers grip the receptor
Mapped how MRI-1891 and related molecules bind CB1. Also reports a 3.3% weight reduction over 28 days for MRI-1891 in a phase 1b trial [37].
ABHD6 and diet-induced obesity
Switching off ABHD6 in reward-center neurons prevented diet-induced obesity and reduced food seeking, in male mice only [32].
SKNY-1, a lab-made relative of THCV
Lowered weight in a zebrafish model of MC4R obesity over 6 days of treatment. A fish model, far from people [30].
The p62 protein and CB1 recycling
Asked whether p62 controls how cells clear CB1 and whether that explains obesity in mice lacking p62. A neutral result [34].
Rimonabant and gene regulation in brain cells
Rimonabant at treatment-like levels changed histone marks in neuronal cells and rat brain tissue, a possible link to its psychiatric effects [1].
Taurine, fat and the CB1 pathway
In mice on a high-fat diet, taurine reduced fat buildup through the endocannabinoid and CB1 axis [36].
CBD plus swimming in obese rats
Looked at metabolic and inflammatory genes with exercise, CBD or both. Mixed results [28].
A new way to make zevaquenabant
Describes a scalable synthesis of a peripheral CB1 blocker. Chemistry, not a test in people [48].
Hemp seed oil and fat cells
In human stem cells in a dish, hemp seed oil nudged developing fat cells toward a calorie-burning type through CB2 [29].
A switch in the CB1 gene that differs between people
Found that common versions of a DNA control region change how strongly the CB1 gene is read, a possible reason responses to cannabinoid drugs vary [35].
No studies of that design are on this page.
What kinds of studies is this evidence built on?
How to read it: each row is one kind of study, and the number at the end of the bar is how many published studies of that kind exist on cannabinoids and obesity. The designs near the top carry the most weight: a meta-analysis pools several trials, and a randomized trial can tell cause from coincidence. The gray bars are narrative reviews, animal studies and laboratory studies: useful for understanding the biology, not for proving that a treatment works in people.
Show as a table
| Study design | Number of studies |
|---|---|
| Meta-analysis | 6 |
| Systematic review | 3 |
| Randomized trial | 35 |
| Clinical trial | 4 |
| Cohort study | 41 |
| Case-control study | 4 |
| Cross-sectional study | 11 |
| Survey | 6 |
| Guideline | 2 |
| Narrative review | 302 |
| Animal study | 156 |
| Laboratory study | 36 |
How big are the effects, in numbers
“It is linked” is not a useful sentence on its own. The clearest set of numbers on substance use in people with obesity comes from a survey of adults with obesity taken during the COVID-19 pandemic. One caveat comes first: it asked about substance use of any kind, alcohol and other drugs included, not cannabis alone [44].
In people with obesity, what traveled with substance use during the pandemic?
How to read it: each row compares people who used substances with people who did not. The dot is the best estimate of how much more often the problem was reported, and the bar around it is the likely range, the confidence interval. The gray line marks no difference: rows to the right of it were more common with substance use. A hollow dot would mean the range crosses that line; none does here.
estimate · likely range (confidence interval) · no difference
Any substance use vs none
- Stockpiling food1.5× more often (1.03–2.18)
- Finding healthy eating harder1.47× more often (1.01–2.16)
- Trouble falling asleep1.64× more often (1.14–2.34)
- Anxiety1.47× more often (1.01–2.14)
Increased use vs unchanged use
- Stress eating6.3× more often (2.4–16.6)
- Missing a weight-loss goal5.0× more often (1.7–14.4)
- Depression4.4× more often (1.3–14.7)
Show as a table
| Comparison | Outcome | Odds ratio (likely range) |
|---|---|---|
| Any use vs none | Food stockpiling | 1.50 (1.03–2.18) |
| Any use vs none | Harder healthy eating | 1.47 (1.01–2.16) |
| Any use vs none | Difficulty falling asleep | 1.64 (1.14–2.34) |
| Any use vs none | Anxiety | 1.47 (1.01–2.14) |
| Increased vs unchanged use | Stress eating | 6.34 (2.41–16.65) |
| Increased vs unchanged use | Difficulty reaching a weight-loss goal | 4.99 (1.74–14.35) |
| Increased vs unchanged use | Depression | 4.42 (1.33–14.65) |
The wide ranges in the second group matter as much as the estimates: “somewhere between 2.4 and 16.6 times” is a strong signal of a link and a weak measure of its size. A second study points the same way from a different angle.
In the same study, obesity with normal blood pressure, sugar and cholesterol did not raise those events on its own (odds ratio 0.98, 95% CI 0.70–1.37) [41]. “Drug use” there was not limited to cannabis, so the number is a caution, not a cannabis finding.
What researchers are testing now
Rimonabant’s failure did not end interest in CB1. It moved the target. The new idea is to block CB1 receptors in fat tissue, the liver and muscle while keeping the drug out of the brain, where the mood effects came from. These are experimental medicines from drug companies, not cannabis and not anything available under a medical marijuana card [2].
How much weight did people lose in the earliest human trials?
How to read it: each row is one experimental drug. The dark bar is the average weight lost on the drug, as a share of starting weight; the light bar under it is the comparison group, where one was reported. The scale runs from 0 to 15 percent of starting weight for every row.
-
CRB-913
2.9% more than placebo (placebo already subtracted) [2]
-
Nimacimab vs placebo
1.52% vs 0.26% on placebo [2]
-
Nimacimab plus semaglutide vs semaglutide alone
13.2% vs 10.25% on semaglutide alone [2]
-
MRI-1891
3.3% from starting weight; no comparison group reported [37]
Show as a table
| Drug | Weight change | Comparison | Source |
|---|---|---|---|
| CRB-913 | −2.9%, placebo-adjusted, day 14 | Placebo (subtracted) | Phase Ia, n = 12, narrative review [2] |
| Nimacimab 200 mg weekly | −1.52% | Placebo −0.26% | Narrative review [2] |
| Nimacimab plus semaglutide | −13.2% | Semaglutide alone −10.25% | Narrative review [2] |
| MRI-1891 | −3.3% over 28 days | None reported | Phase 1b, structural study [37] |
Numbers from animals are much larger, and they belong in a separate sentence. In mice with diet-induced obesity, CRB-913 led to 22% weight loss by day 18, and 32.6% when combined with tirzepatide [2]. Results in mice often shrink or vanish in people, which is why those figures are not on the chart. A peripheral blocker called zevaquenabant is still at the chemistry stage, with a new way to manufacture it published in 2026 [48].
| Rung | What it can show | Molecules on this rung |
|---|---|---|
| Lab and animal studies | How a drug works; not whether it helps people | SKNY-1 in zebrafish [30]; zevaquenabant, chemistry [48]; CRB-913 in mice [2] |
| Phase 1 trials | Safety and a first signal, in a few people over days or weeks | CRB-913 [2]; MRI-1891 [37] |
| Controlled trials against placebo or another drug | Whether the effect is real and safe when compared directly | Nimacimab results reported against placebo and semaglutide [2]; rimonabant reached the market and was withdrawn [1] |
| Meta-analysis | The combined answer across many trials | None of the new peripheral blockers has enough trials to pool yet |
Where the evidence runs out
A page like this is only honest if it is as clear about the holes as about the findings. These are the specific ones.
- No long-term weight data in people who use cannabis. Nobody has followed adults with obesity who use medical cannabis for years and measured what happened to their weight. Every human study above is a survey, a snapshot or a short trial of a different drug.
- Links are not causes. The bariatric survey, the pandemic survey and the pregnancy cohort all show that cannabis or substance use went together with something else [27][44][38]. None can show which came first.
- The newest drugs are known mostly from summaries. The review that reports CRB-913 and nimacimab relied in part on conference posters and company press releases, because peer-reviewed papers did not exist yet; long-term outcomes, durability and effects on heart disease remain largely unknown [2].
- Animal models do not translate neatly. The zebrafish study of SKNY-1 lasted 6 days with no data on blood levels [30]; the ABHD6 work used male mice only [32]. Promising biology is still biology.
- The genetics was studied in narrow groups. The Framingham analysis of CB1 and FAAH genes included only people of European ancestry and only common variants [13]; the MC4R meal-challenge test involved 11 carriers and 15 controls [12].
- Some numbers are left out on purpose. The obesity literature contains studies of tobacco laws and of exercise after surgery [46][47]. They are real findings about other questions, and repeating their percentages next to cannabis would suggest a link they never tested.
Cannabis forms and their risks with obesity
Cannabis is not one thing. It is smoked, vaped, eaten, held under the tongue, rubbed on the skin or taken as a prescription capsule, and the risks are not the same for every route. Some follow from the smoke or vapor, some from THC itself in any form, and some from sharing a device. Choose the way you use it, or are thinking of using it, to see what applies.
How do you use it, or plan to?
Choose the closest one; most people combine more than one.
Specific to smoking: joints, blunts, pipes, bongs
Smoke is burned plant material, and it irritates the airways and causes cough. With obesity, the lungs already have less room to expand, and if sleep apnea or hypoventilation is part of the picture, smoke lands on airways that are struggling at night. Blunts add tobacco on top.
Specific to vaping and dabbing
There is no smoke, but the hot aerosol from a dry-herb vaporizer, an oil cartridge or a dab rig travels down the same airways. Concentrates such as wax, shatter and rosin carry much more THC per puff, so effects, appetite included, come on faster and stronger.
Specific to edibles, drinks and capsules
Gummies, chocolate and baked goods carry their own calories, which count. Swallowed THC passes through the liver before it reaches the blood, so it takes longer to start and lasts longer than inhaled THC. Taking a second dose because “the first one is not working” is a common way people take far more than they meant to.
Specific to tinctures, oils and sprays
Held under the tongue or sprayed inside the cheek, part of the dose is absorbed there and skips the lungs entirely. Whatever is swallowed still goes through the liver, and the THC in it acts on appetite the same way.
Specific to topicals and patches
Creams, balms and salves act mainly where they are applied, and little reaches the bloodstream. Transdermal patches are different: they are designed to deliver cannabinoids into the blood, so the points about every form below apply to them.
Specific to prescription cannabinoids
Dronabinol (Marinol, Syndros), nabilone (Cesamet) and cannabidiol (Epidiolex) are FDA-approved medicines, prescribed by a doctor and filled at a pharmacy, not obtained through a medical marijuana card. Dronabinol is used to restore appetite in people with AIDS who are losing weight and, like nabilone, to control nausea from chemotherapy [31].
Shared devices
Passing a joint, a pipe or a vape pen around passes saliva, and with it colds, flu and other infections. That risk belongs to the shared device, not to cannabis.
True of every form
- THC raises appetite whether it is smoked, vaped, eaten or held under the tongue.
- The liver processes cannabinoids, which is how they interact with other medicines, including some for diabetes, blood pressure and mood.
- THC can cause drowsiness, which adds to other sedating drugs and matters more with untreated sleep apnea.
- Driving after using any form is impaired driving.
Choosing a form is a conversation for the appointment, not a decision this page can make for you.
All forms as a table
| Form | What it avoids | What remains |
|---|---|---|
| Smoking | Nothing in particular | Smoke in the airways, shared-device infections, THC effects of every form |
| Vaping and dabbing | Burning plant material | Hot aerosol in the airways, strong concentrates, shared-device infections, THC effects of every form |
| Edibles, drinks, capsules | The airways and shared mouthpieces | Extra calories, delayed and longer effect, risk of a repeat dose, the liver, THC effects of every form |
| Tinctures and sprays | The airways and shared mouthpieces | The liver for whatever is swallowed, THC effects of every form |
| Topical creams and balms | The airways; most of the bloodstream | Local skin reactions; ask about interactions anyway |
| Transdermal patches | The airways | Cannabinoids in the blood, so the effects of every form |
| Prescription cannabinoids | Unmeasured doses | A prescription medicine with its own label, side effects and interactions [31] |
Safety: side effects, drug interactions and bariatric surgery
The side effects of THC are well described in the labels of the prescription versions: drowsiness, dizziness, anxiety, confusion and memory problems, and less often a rapid heartbeat or fainting [31]. Most of them grow with the dose, and they matter more if you already live with high blood pressure, poor sleep or low mood. Increased appetite belongs on the same list; for someone managing obesity it is a side effect, not a benefit.
Interactions worth raising at the appointment
None of these means “never”. They are the medicines a physician will ask about, so it helps to have the names and doses written down.
Diabetes medicines, including insulin
THC raises appetite through CB1 [27], and eating more, or at odd hours, shifts blood sugar. On insulin or a sulfonylurea, which can push sugar too low when meals change, that is worth planning for with your prescriber rather than discovering on your own.
Obesity medicines such as semaglutide or tirzepatide
These drugs work largely by turning appetite down; THC turns it up. No study on this page measured the two together in people, so the honest answer is that they pull in opposite directions and nobody has tested how that plays out. Tell whoever prescribes your weight medicine.
Blood pressure and heart medicines
THC can cause a rapid heartbeat, dizziness and, less often, fainting [31]. Added to medicines that lower blood pressure, that can mean light-headedness or a fall, especially in the first days.
Antidepressants, antipsychotics and mood stabilizers
Sleeping pills, benzodiazepines, opioids and alcohol
THC adds to the drowsiness of other sedating drugs and of alcohol [31]. With obesity that matters twice, because sedation deepens the breathing problems of untreated sleep apnea and hypoventilation.
Before bariatric surgery
If you are preparing for a sleeve, a bypass or another weight-loss operation, the most useful numbers on this page come from a 2026 prospective cohort study of patients who had a urine drug screen before surgery. Patients with a positive screen, for any substance the test covered, did worse in the month after the operation [40].
How did patients with a positive drug screen do in the 30 days after surgery?
How to read it: the dark bar is patients with a positive screen before surgery, the light bar is patients with a negative one. The scale runs from 0 to 10 percent of patients.
-
Complications within 30 days
5.4% with a positive screen vs 1.9% with a negative one [40]
-
Readmission to hospital within 30 days
7.1% with a positive screen vs 1.6% with a negative one [40]
The authors recommend screening before surgery so the team can plan for tolerance, heightened pain sensitivity and withdrawal [40]. The practical step for you is simpler: tell your surgeon and your anesthesiologist exactly what you use, how often and in what form, well before the operation. It changes the anesthetic plan, not whether you deserve the surgery. After surgery, the survey of bariatric patients found cannabis use going together with more anxiety and binge eating [27], so the conversation is worth continuing with your bariatric team afterward.
This section summarizes published research. It does not replace advice from your surgeon, anesthesiologist or the physician who prescribes your medicines.
Talk to a licensed physician about how this applies to your own treatment.
Who should not use cannabis for this
For some people the answer is not “be careful” but “not now”. These are the situations where a physician is most likely to advise against THC, whatever the form.
- Pregnancy and breastfeeding. Children exposed to cannabis in the womb had more body fat in early childhood [38], on top of the other known risks to a developing baby.
- A history of psychosis or schizophrenia. Prescription THC carries a psychiatric warning [31], and the CB1 receptor’s role in mood is exactly what ended rimonabant [2]. See cannabis and psychosis.
- Untreated sleep apnea or obesity hypoventilation, for inhaled forms and anything sedating. Smoke and vapor reach airways that are already narrowed, and added drowsiness deepens the problem [19] [24]. Get the sleep study and the treatment first.
- Binge-eating disorder. A drug that raises appetite works against the core of the illness, and after bariatric surgery cannabis use went together with more binge eating [27].
- Teenagers. In animal studies, heavy activation of the endocannabinoid system during adolescence disrupted adult fat tissue [33]; among US teens, marijuana use went with poorer drink habits [39]. Medical programs for minors are narrow and set by each state.
- Heart disease or uncontrolled blood pressure. THC can cause a rapid heartbeat and fainting [31]; that needs a cardiologist’s view first.
- A depression or anxiety disorder that is not yet under control. Not an absolute bar, but a reason to treat the mood disorder first and decide about cannabis with the clinician who knows it [2].
Talk to a licensed physician about whether any of these apply to you.
Is obesity a qualifying condition for a medical marijuana card?
In most states, obesity is not on the list on its own. Every medical marijuana program keeps its own list of qualifying conditions, and a physician has to match you against that wording, not against your weight. Your state decides; neither we nor your doctor can add a condition to it.
That does not end the question. Obesity rarely comes alone, and several of the conditions that travel with it, chronic pain, arthritis, anxiety, insomnia, are on many state lists. Some programs also let a physician certify a condition that is not named, or accept petitions to add new ones. Which of these applies to you is a question for the evaluation, and it is one of the reasons the evaluation exists.
Obesity is named in your state
The rarest case. Bring records that show the diagnosis and how long you have had it, and the physician evaluates you against that listed condition.
A condition you also have is listed
The most common route. The qualifying diagnosis is the pain, the arthritis or the anxiety, and your obesity is part of the history the physician weighs, especially for safety.
Neither is on the list
Then a card may not be available for you where you live. Ask whether your state allows physician discretion or petitions, and keep treating the obesity itself with your regular doctor.
What else do you live with?
Pick what a doctor has diagnosed; state lists name diagnoses, not symptoms.
Chronic pain
Chronic or severe pain is one of the most widely listed conditions, and with obesity it is often back or knee pain that limits how much you can move. What the research says about cannabis and chronic pain.
Arthritis
Excess weight loads the knees and hips, and osteoarthritis is one of its most common companions [9]. Many programs list arthritis directly or cover it under chronic pain. Cannabis and arthritis.
Anxiety
Anxiety is listed in some states and not in others, and the research is more mixed than many expect. Cannabis and anxiety, strongest evidence first.
PTSD
Post-traumatic stress disorder is one of the conditions most often named on state lists. A formal diagnosis is what the physician looks for. Cannabis and PTSD.
Depression
Depression is rarely listed on its own, and it is also a reason for caution with THC, as the safety section explains. Cannabis and depression.
Insomnia
Some states list insomnia; with obesity, poor sleep is worth a sleep study first, because apnea can look exactly like it. Cannabis and insomnia.
Migraine
Migraine is listed in a number of states, sometimes under chronic or severe pain. Cannabis and migraine.
None of these
Then it comes down to whether your state allows a physician to certify an unlisted condition. Many do not, and that is worth knowing before you apply. Medical marijuana laws by state.
What the program in your state involves
Qualifying is the first of two doors. In most states a physician’s recommendation is followed by registration with the state program, which issues the card itself and keeps you in a confidential patient registry; in a few, the recommendation alone is what a dispensary asks for. Either way, you buy at licensed dispensaries, where products are lab-tested and labeled with their THC and CBD content. Most programs also let a registered caregiver buy on behalf of a patient who cannot, under rules each state sets. If you travel, some states accept out-of-state cards and many do not; which states accept out-of-state cards is worth checking before a trip, not at the counter.
The legal status, possession limits, home cultivation rules and taxes all differ from state to state, and they change. They are set out, state by state, on the laws and regulations pages.
What a card changes compared with buying recreationally
In states where adults can already buy cannabis, a medical card can still change three things: what you pay, because many states tax medical purchases less; how much you may hold or grow; and who can buy at all, since medical programs in some states admit adults under 21. In other states the difference is small, and it is fair to say so. The details, with the tax side worked through, are in medical vs recreational cannabis taxes and the difference between medical and recreational cannabis. None of this makes the card a treatment for obesity.
Whether the card pays for itself is simple arithmetic you can do with your own numbers:
- Your monthly spend. What you already spend at a dispensary in a typical month.
- The tax gap. Your state’s tax on recreational purchases minus its tax on medical ones, from your state’s laws and regulations page. Multiply your monthly spend by that gap: this is what the card saves you each month.
- The cost of the card. The evaluation fee shown for your state, plus any state registration fee.
- The payback. Divide the cost of the card by the monthly saving. If the answer is longer than the card is valid in your state, the card does not pay for itself on tax alone, and only the other reasons above are left.
Legal protections: firearms, employment and privacy
- Firearms. A state card does not change federal firearms law, which treats marijuana separately from state programs. Read gun ownership with a medical marijuana card (written for Ohio, with the federal rule that applies everywhere) before you apply if this matters to you.
- Employment. Some states protect medical patients from being fired for a card alone; many allow employers to keep drug-free policies, and jobs under federal safety rules, such as commercial driving, follow federal testing whatever the state says.
- Privacy. State patient registries are confidential, and your medical records are protected health information under HIPAA [49]. Who else may see the registry is set by state law, and your state’s page says.
What this means if you are considering it
If you have read this far, you already know more than most people walking into the appointment. The goal of that appointment is not to talk you into anything. It is a licensed physician looking at your diagnoses, your medicines and your goals, and telling you plainly whether a recommendation fits, and what to watch for if it does.
What to bring to the appointment
Tap each item as you get it ready.
Questions worth asking
- Which of my diagnoses actually qualifies in my state, and which does not?
- How does THC’s effect on appetite fit with the weight plan I already have?
- Do any of my medicines, especially for diabetes, blood pressure or mood, change what you would suggest?
- Given my sleep and breathing, which forms would you rule out?
- What should make me stop and call you?
An evaluation makes sense if
- You live with a condition such as chronic pain, arthritis, insomnia or anxiety that your state may list.
- Your usual treatments for it have not been enough, or carry side effects you want to avoid.
- You are willing to keep treating your weight with your regular doctor alongside it.
It is not the right step if
- Weight loss is the only thing you want from it; nothing here suggests it helps.
- You are pregnant, breastfeeding, or have a history of psychosis.
- You have bariatric surgery coming up and have not yet spoken with your surgical team.
How to get a medical marijuana card online
The whole evaluation happens online, with a physician licensed in your state; there is nowhere to drive and no waiting room to sit in. These are the four steps, with what each one asks of you.
Fill in the intake form
Your state, your conditions, your medicines. Have the list from the section above at hand.
Meet a physician licensed in your state
You agree the time with the physician. Keep an hour free rather than a minute, in case the previous patient runs long.
Receive the signed recommendation
If the physician finds that you qualify, the signed recommendation can arrive in as little as 15 minutes after the appointment, depending on your state.
Register with your state
Where the state issues a card, you apply to its program; how long that takes is up to the state agency, not to us.
What you end up with
A recommendation signed by a physician licensed in your state and, in states that issue them, a card from the state program. That is what a licensed dispensary asks to see. Not a prescription, and not a weight-loss plan.
Across 250 reviews from patients in the states where we are licensed. We do not sort them by score and do not hide the low ones.
- 150,000+patients evaluated — everyone who has been through an appointment with us, in every state where we are licensed
- Since 2017doing only this: online evaluations for medical cannabis programs, and nothing else on the side
Your recommendation is kept with your account and documents. How the evaluation works, in more detail, is on the medical card page. Veterans and people on a low income can check the veterans program and the low-income program.
What the evaluation costs, and what if you change your mind
The fee depends on your state’s program, so it is shown for your state, before you pay, once you choose your state. Before you check out, look for three things on that page:
- What the price includes. The physician’s evaluation and the signed recommendation. A state registration fee, where your state charges one, is paid to the state, not to us.
- Coupons and vouchers. If you have a promo code or a prepaid voucher, enter it at checkout, and read what that voucher covers before you start. Current offers are on the coupons page.
- Cancellation and refunds. The conditions are set out in the terms of service. Read them before you pay, not after the appointment.
Renewing your card
A recommendation and a state card do not last forever; how long they are valid is set by each state. Renew before the expiry date rather than after it, because a lapsed card means a gap in legal access, and some states ask for a full new application once it has expired. The renewal starts the same way, from your account, with an appointment that reviews what has changed since last time: your weight, your medicines, how the treatment has gone. If you have lost your card, what to do if your card was lost walks through the replacement.
Questions patients ask about cannabis and obesity
Does cannabis help with weight loss?
Nothing in the research behind this page shows that it does. THC raises appetite through the CB1 receptor [27], and none of the human studies tested cannabis as a weight-loss treatment. The cannabinoid drug that was tested for weight, rimonabant, blocked CB1 instead, and it was withdrawn over psychiatric side effects [1].
Does THC make you gain weight?
It makes you hungrier, in any form [27], and that can add up to weight gain, especially with edibles that carry their own calories. Whether it does for a particular person depends on how often, how much and what they eat when the hunger comes. No long-term study in adults with obesity has measured it.
Is CBD different?
Yes. CBD does not switch CB1 on the way THC does, and what is true of THC and appetite does not transfer to a CBD-only product. Studies of CBD and weight so far are in animals and cells, such as obese rats [28], so there is no answer yet for people.
Can I use cannabis before bariatric surgery?
Tell your surgical team before anything else. In a 2026 cohort study, patients with a positive drug screen before surgery needed more anesthetic and had more complications (5.4% vs 1.9%) and readmissions (7.1% vs 1.6%) within 30 days [40]. Your surgeon and anesthesiologist decide whether and when to stop.
Is obesity a qualifying condition for a medical card?
In most states it is not listed on its own. People with obesity often qualify through a condition that is listed, such as chronic pain or arthritis. Each state’s list is on the laws and regulations pages, and a licensed physician makes the call at the evaluation.
Is obesity considered a chronic disease?
Is obesity considered a disability?
Not automatically. Under federal disability law the question is whether a condition substantially limits major life activities, and courts have decided obesity cases differently, often looking at whether it is severe or caused by another medical condition. The conditions that come with it, such as osteoarthritis or sleep apnea, can count on their own. A disability attorney or your state’s disability office can tell you where you stand.
Is there an obesity hotline?
There is no single national obesity hotline. The best first call is your regular doctor, who can refer you to an obesity medicine specialist, a dietitian or a bariatric program. If weight is wearing on your mood and you are in crisis, call or text 988, the Suicide & Crisis Lifeline, at any hour.
Is delta-8 THC part of the medical program?
Generally not. Delta-8 is usually made from hemp and sold outside medical programs, in shops with none of the lab-testing rules that licensed dispensaries follow, and its legal status differs by state. It acts on the same CB1 receptor, so it raises appetite too. Ohio’s rules are explained in is delta-8 THC legal in Ohio.
How do I choose a dispensary?
Buy only from a dispensary licensed by your state’s program, where products are lab-tested and labeled with their THC and CBD content. Ask the staff about calories and serving size for edibles, and bring your medicine list; a good dispensary would rather spend five minutes on it than sell you the wrong product.
Can I use my medical card in another state?
Sometimes. Some states accept out-of-state cards, some only with their own registration, and many not at all. Check which states accept out-of-state cards before you travel, and never carry cannabis across state lines.
What if I lose my medical card?
Your registration does not disappear with the plastic; the state program can reissue it. The steps are in what to do if your card was lost, and other common questions are on the medical card FAQ.
More research on cannabis and obesity
This page cites a selection of studies. Our research library holds every study we track on cannabis and obesity, from laboratory work to clinical trials, and lets you filter them by cannabinoid, study type and year.
- studies
- 1,800+
- in people
- 860+
- clinical trials
- 100+
Other qualifying conditions
The conditions that most often travel with obesity each have their own page, written the same way: what the research shows, strongest evidence first.
References
49 sources
- 1. Therapeutically relevant rimonabant exposure drives epigenetic remodeling in neuronal cells and rat brain tissue. DOI: 10.1007/s00204-026-04369-0 PMID: 41991728
- 2. Overview of Novel Mechanisms in Obesity Pharmacotherapy and Implications for Cardiovascular Disease: A Narrative Review. DOI: 10.1007/s11883-026-01438-8 PMID: 42360622
- 3. Centers for Disease Control and Prevention. Adult Obesity Facts. 2024.
- 4. Centers for Disease Control and Prevention. Adult BMI Categories. 2024.
- 5. CDC, National Center for Health Statistics. Obesity and Severe Obesity Prevalence in Adults: United States, August 2021–August 2023 (NCHS Data Brief No. 508). 2024.
- 6. Centers for Disease Control and Prevention. New Adult Obesity ICD-10-CM Codes: Partner Promotion Materials. 2024.
- 7. National Heart, Lung, and Blood Institute. Aim for a Healthy Weight: Assessing Your Weight and Health Risk.
- 8. Centers for Disease Control and Prevention. Childhood Obesity Facts. 2024.
- 9. National Institute of Diabetes and Digestive and Kidney Diseases. Health Risks of Overweight & Obesity.
- 10. Centers for Medicare & Medicaid Services. ICD-10 Codes. 2025.
- 11. National Institute of Diabetes and Digestive and Kidney Diseases. Factors Affecting Weight & Health.
- 12. Obesity due to MC4R deficiency is associated with reduced cholesterol, triglycerides and cardiovascular disease risk. DOI: 10.1038/s41591-025-03976-1 PMID: 41102563
- 13. Variants in the CNR1 and the FAAH genes and adiposity traits in the community. DOI: 10.1038/oby.2008.608 PMID: 19165169
- 14. Racial and sex differences in the polymorphisms of the endocannabinoid receptor genes in obesity. DOI: 10.1016/j.jdiacomp.2020.107682 PMID: 32732136
- 15. American Heart Association, American College of Cardiology, Heart Failure Society of America. 2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure. 2022.
- 16. National Institute of Diabetes and Digestive and Kidney Diseases. Insulin Resistance & Prediabetes.
- 17. Office on Women’s Health, US Department of Health and Human Services. Polycystic Ovary Syndrome.
- 18. Endocrine Society, Journal of Clinical Endocrinology & Metabolism. Altered Expression of Aromatase and Estrogen Receptors in Adipose Tissue From Men With Obesity or Type 2 Diabetes. 2025.
- 19. National Heart, Lung, and Blood Institute. Obesity Hypoventilation Syndrome.
- 20. National Cancer Institute. Obesity and Cancer. 2025.
- 21. American Academy of Dermatology. Do You Have Hair Loss or Hair Shedding?
- 22. National Institute of Diabetes and Digestive and Kidney Diseases. Symptoms & Causes of GER & GERD.
- 23. CDC, Morbidity and Mortality Weekly Report. Body Mass Index and Risk for COVID-19–Related Hospitalization, Intensive Care Unit Admission, Invasive Mechanical Ventilation, and Death. 2021.
- 24. National Heart, Lung, and Blood Institute. Sleep Apnea.
- 25. CDC, National Center for Health Statistics. Prevalence of Overweight, Obesity, and Severe Obesity Among Adults Aged 20 and Over: United States, 1960–1962 Through 2017–2018. 2020.
- 26. What Role Does the Endocannabinoid System Play in the Pathogenesis of Obesity? DOI: 10.3390/nu13020373 PMID: 33530406
- 27. Cannabis use following bariatric surgery is associated with anxiety and maladaptive eating. DOI: 10.1016/j.soard.2023.09.009 PMID: 37863791
- 28. Effects of chronic swimming exercise and cannabidiol on metabolic and i̇nflammatory gene expression in obese rats. DOI: 10.1186/s13102-026-01635-7 PMID: 41787558
- 29. Adipogenicity-induced human mesenchymal stem cells treated with hemp seed oil stimulate brown-like adipocytes and decrease adipokine levels through the activation of cannabinoid receptor 2 (CB2). DOI: 10.1186/s42238-025-00343-2 PMID: 41258240
- 30. SKNY-1, a THCV Analog, Produces Weight Loss, Lipid Normalization and Attenuation of Reward-Associated Behaviors in an mc4r(G894C) Zebrafish Model of Obesity. DOI: 10.3390/ijms27104321 PMID: 42196303
- 31. MedlinePlus, US National Library of Medicine. Dronabinol.
- 32. ABHD6 loss-of-function in mesoaccumbens postsynaptic but not presynaptic neurons prevents diet-induced obesity in male mice. DOI: 10.1038/s41467-024-54819-5 PMID: 39681558
- 33. Overactivation of the Endocannabinoid System in Adolescence Disrupts Adult Adipose Organ Function in Mice. DOI: 10.3390/cells13050461 PMID: 38474425
- 34. Exploring cannabinoid receptor CB1 autophagy and the obesity phenotype of p62-deficient mice. DOI: 10.1016/j.bbrep.2026.102571 PMID: 42004545
- 35. Disease-associated polymorphisms within the conserved ECR1 enhancer differentially regulate the tissue-specific activity of the cannabinoid-1 receptor gene promoter; implications for cannabinoid pharmacogenetics. DOI: 10.1002/humu.23931 PMID: 31608546
- 36. Taurine attenuates lipid accumulation via the eCB-CB1 axis: evidence from adipose metabolomics in HFD-fed mice and 3D adipocyte spheroids. DOI: 10.3389/fnut.2026.1782392 PMID: 41867680
- 37. Structural mechanism of CB1R binding to peripheral and biased inverse agonists. DOI: 10.1038/s41467-024-54206-0 PMID: 39695122
- 38. Fetal Exposure to Cannabis and Childhood Metabolic Outcomes: The Healthy Start Study. DOI: 10.1210/clinem/dgac101 PMID: 35357471
- 39. E-cigarette and marijuana use and the attainment of obesity prevention guidelines among U.S. adolescents. DOI: 10.1016/j.pmedr.2021.101445 PMID: 34221851
- 40. Impact of Preoperative Toxicological Screening on Perioperative Anesthetic Management and Short-Term Outcomes Following Metabolic and Bariatric Surgery: A Prospective Observational Study. DOI: 10.1007/s11695-026-08534-3 PMID: 41915289
- 41. Cardiovascular outcomes in metabolically healthy Asian-American population with obesity (18-44 years): Insights from the National Inpatient Sample. DOI: 10.1016/j.obpill.2025.100158 PMID: 39927248
- 42. Genetic polymorphisms in genes related to risk-taking behaviors predicting body mass index trajectory among Mexican American adolescents. DOI: 10.1111/ijpo.12151 PMID: 27228958
- 43. Neuroanatomical profile of BMI implicates impulsive delay discounting and general cognitive ability. DOI: 10.1002/oby.23880 PMID: 37853988
- 44. Substance use, mental health and weight-related behaviors during the COVID-19 pandemic in people with obesity. DOI: 10.1111/cob.12440 PMID: 33539652
- 45. Weight gain, weight management and medical care for individuals living with overweight and obesity during the COVID-19 pandemic (EPOCH Study). DOI: 10.1002/osp4.591 PMID: 36238224
- 46. Beyond Tobacco Prevention: The Effects of Tobacco 21 Laws on Young Adults’ Body Weight. DOI: 10.1002/hec.70120 PMID: 42332341
- 47. Impact of high-intensity interval training vs. moderate-intensity continuous training combined with strength training on physical and metabolic outcomes in post-bariatric surgery patients with sarcopenic obesity. DOI: 10.1186/s12891-026-09722-z PMID: 41947110
- 48. A Novel Approach for the Synthesis of Peripherally Acting Dual Target Inhibitor of Cannabinoid-1 (CB1 Receptor) and Inducible Nitric Oxide Synthase (iNOS) (S-MRI-1867/Zevaquenabant). DOI: 10.3390/molecules31030515 PMID: 41683492
- 49. US Department of Health and Human Services. Health Information Privacy (HIPAA).